{"id":5704,"date":"2025-08-15T14:49:41","date_gmt":"2025-08-15T18:49:41","guid":{"rendered":"https:\/\/alcanzaclinical.com\/?p=5704"},"modified":"2025-08-15T14:55:15","modified_gmt":"2025-08-15T18:55:15","slug":"5704-2","status":"publish","type":"post","link":"https:\/\/alcanzaclinical.com\/de\/5704-2\/","title":{"rendered":"Alcanza Doses First Patient in Novel Alzheimer’s Trial"},"content":{"rendered":"

\"\"<\/p>\n

The Alcanza team at NeuroStudies has successfully dosed the first patient in a first-in-human clinical trial for a novel antibody targeting Alzheimer’s Disease.<\/p>\n

Alcanza is honored to be selected as one of only three U.S. sites entrusted with this important milestone. The first patient enrolled was the first person globally, out of more than 8 billion people, to receive this investigational therapy. It\u2019s a powerful reminder of the significance of early-phase research in advancing new treatment possibilities.<\/p>\n

Sincere thanks go to Dr. Marshall L Nash, MD, CPI, FAHA, FAPCR, FAAN, and the dedicated NeuroStudies site staff, especially our Site Director Adrienne Hilliard, Site Manager Stefan Ilic, and Lead CRC Stephen Bocarro, as well as our Pharmacy Manager, Veronica S. Walker, PharmD, SHRM-PMQ and Pharmacy Lead Carolyn Simms, CPhT, CSPT, for their commitment to excellence.<\/p>\n

We are grateful for the confidence placed in us by the FDA, IRB, CRO, sponsor, and our colleagues at Alcanza as we continue our shared mission to advance new treatment options for patients and families impacted by Alzheimer’s Disease.<\/p>","protected":false},"excerpt":{"rendered":"

The Alcanza team at NeuroStudies has successfully dosed the first patient in a first-in-human clinical trial for a novel antibody targeting Alzheimer’s Disease. Alcanza is honored to be selected as one of only three U.S. sites entrusted with this important milestone. The first patient enrolled was the first person globally, out of more than 8 […]<\/p>\n","protected":false},"author":22,"featured_media":5705,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[13],"tags":[],"class_list":["post-5704","post","type-post","status-publish","has-post-thumbnail","hentry","category-company-news"],"acf":[],"yoast_head":"\nAlcanza Doses First Patient in Novel Alzheimer's Trial - Alcanza Clinical Research<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/alcanzaclinical.com\/de\/5704-2\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alcanza Doses First Patient in Novel Alzheimer's Trial\" \/>\n<meta property=\"og:description\" content=\"The Alcanza team at NeuroStudies has successfully dosed the first patient in a first-in-human clinical trial for a novel antibody targeting Alzheimer’s Disease. Alcanza is honored to be selected as one of only three U.S. sites entrusted with this important milestone. The first patient enrolled was the first person globally, out of more than 8 […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/alcanzaclinical.com\/de\/5704-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Alcanza Clinical Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=100082162274544\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-15T18:49:41+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-15T18:55:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/alcanzaclinical.com\/wp-content\/uploads\/2025\/08\/LinkedIn-Templates-9.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"627\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sarah Belanus\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sarah Belanus\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/alcanzaclinical.com\/5704-2\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/alcanzaclinical.com\/5704-2\/\"},\"author\":{\"name\":\"Sarah Belanus\",\"@id\":\"https:\/\/alcanzaclinical.com\/#\/schema\/person\/7c0eb32da58e72e6d6f3bda3c4252349\"},\"headline\":\"Alcanza Doses First Patient in Novel Alzheimer’s Trial\",\"datePublished\":\"2025-08-15T18:49:41+00:00\",\"dateModified\":\"2025-08-15T18:55:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/alcanzaclinical.com\/5704-2\/\"},\"wordCount\":185,\"publisher\":{\"@id\":\"https:\/\/alcanzaclinical.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/alcanzaclinical.com\/5704-2\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/alcanzaclinical.com\/wp-content\/uploads\/2025\/08\/LinkedIn-Templates-9.png\",\"articleSection\":[\"Company News\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/alcanzaclinical.com\/5704-2\/\",\"url\":\"https:\/\/alcanzaclinical.com\/5704-2\/\",\"name\":\"Alcanza Doses First Patient in Novel Alzheimer's Trial - Alcanza Clinical Research\",\"isPartOf\":{\"@id\":\"https:\/\/alcanzaclinical.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/alcanzaclinical.com\/5704-2\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/alcanzaclinical.com\/5704-2\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/alcanzaclinical.com\/wp-content\/uploads\/2025\/08\/LinkedIn-Templates-9.png\",\"datePublished\":\"2025-08-15T18:49:41+00:00\",\"dateModified\":\"2025-08-15T18:55:15+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/alcanzaclinical.com\/5704-2\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/alcanzaclinical.com\/5704-2\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\/\/alcanzaclinical.com\/5704-2\/#primaryimage\",\"url\":\"https:\/\/alcanzaclinical.com\/wp-content\/uploads\/2025\/08\/LinkedIn-Templates-9.png\",\"contentUrl\":\"https:\/\/alcanzaclinical.com\/wp-content\/uploads\/2025\/08\/LinkedIn-Templates-9.png\",\"width\":1200,\"height\":627},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/alcanzaclinical.com\/5704-2\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/alcanzaclinical.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alcanza Doses First Patient in Novel Alzheimer’s Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/alcanzaclinical.com\/#website\",\"url\":\"https:\/\/alcanzaclinical.com\/\",\"name\":\"Alcanza Clinical Research\",\"description\":\"Clinical Research for All\",\"publisher\":{\"@id\":\"https:\/\/alcanzaclinical.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/alcanzaclinical.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/alcanzaclinical.com\/#organization\",\"name\":\"Alcanza Clinical Research\",\"url\":\"https:\/\/alcanzaclinical.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\/\/alcanzaclinical.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/alcanzaclinical.com\/wp-content\/uploads\/2026\/11\/cropped-logo-300x59-1.webp\",\"contentUrl\":\"https:\/\/alcanzaclinical.com\/wp-content\/uploads\/2026\/11\/cropped-logo-300x59-1.webp\",\"width\":300,\"height\":59,\"caption\":\"Alcanza Clinical Research\"},\"image\":{\"@id\":\"https:\/\/alcanzaclinical.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/profile.php?id=100082162274544\",\"https:\/\/www.linkedin.com\/company\/alcanza-clinical\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/alcanzaclinical.com\/#\/schema\/person\/7c0eb32da58e72e6d6f3bda3c4252349\",\"name\":\"Sarah Belanus\",\"url\":\"https:\/\/alcanzaclinical.com\/de\/author\/sarahcellsignalmarketing-com\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Alcanza Doses First Patient in Novel Alzheimer's Trial - Alcanza Clinical Research","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/alcanzaclinical.com\/de\/5704-2\/","og_locale":"de_DE","og_type":"article","og_title":"Alcanza Doses First Patient in Novel Alzheimer's Trial","og_description":"The Alcanza team at NeuroStudies has successfully dosed the first patient in a first-in-human clinical trial for a novel antibody targeting Alzheimer’s Disease. Alcanza is honored to be selected as one of only three U.S. sites entrusted with this important milestone. The first patient enrolled was the first person globally, out of more than 8 […]","og_url":"https:\/\/alcanzaclinical.com\/de\/5704-2\/","og_site_name":"Alcanza Clinical Research","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=100082162274544","article_published_time":"2025-08-15T18:49:41+00:00","article_modified_time":"2025-08-15T18:55:15+00:00","og_image":[{"width":1200,"height":627,"url":"https:\/\/alcanzaclinical.com\/wp-content\/uploads\/2025\/08\/LinkedIn-Templates-9.png","type":"image\/png"}],"author":"Sarah Belanus","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Sarah Belanus","Est. reading time":"2\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/alcanzaclinical.com\/5704-2\/#article","isPartOf":{"@id":"https:\/\/alcanzaclinical.com\/5704-2\/"},"author":{"name":"Sarah Belanus","@id":"https:\/\/alcanzaclinical.com\/#\/schema\/person\/7c0eb32da58e72e6d6f3bda3c4252349"},"headline":"Alcanza Doses First Patient in Novel Alzheimer’s Trial","datePublished":"2025-08-15T18:49:41+00:00","dateModified":"2025-08-15T18:55:15+00:00","mainEntityOfPage":{"@id":"https:\/\/alcanzaclinical.com\/5704-2\/"},"wordCount":185,"publisher":{"@id":"https:\/\/alcanzaclinical.com\/#organization"},"image":{"@id":"https:\/\/alcanzaclinical.com\/5704-2\/#primaryimage"},"thumbnailUrl":"https:\/\/alcanzaclinical.com\/wp-content\/uploads\/2025\/08\/LinkedIn-Templates-9.png","articleSection":["Company News"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/alcanzaclinical.com\/5704-2\/","url":"https:\/\/alcanzaclinical.com\/5704-2\/","name":"Alcanza Doses First Patient in Novel Alzheimer's Trial - Alcanza Clinical Research","isPartOf":{"@id":"https:\/\/alcanzaclinical.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/alcanzaclinical.com\/5704-2\/#primaryimage"},"image":{"@id":"https:\/\/alcanzaclinical.com\/5704-2\/#primaryimage"},"thumbnailUrl":"https:\/\/alcanzaclinical.com\/wp-content\/uploads\/2025\/08\/LinkedIn-Templates-9.png","datePublished":"2025-08-15T18:49:41+00:00","dateModified":"2025-08-15T18:55:15+00:00","breadcrumb":{"@id":"https:\/\/alcanzaclinical.com\/5704-2\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/alcanzaclinical.com\/5704-2\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/alcanzaclinical.com\/5704-2\/#primaryimage","url":"https:\/\/alcanzaclinical.com\/wp-content\/uploads\/2025\/08\/LinkedIn-Templates-9.png","contentUrl":"https:\/\/alcanzaclinical.com\/wp-content\/uploads\/2025\/08\/LinkedIn-Templates-9.png","width":1200,"height":627},{"@type":"BreadcrumbList","@id":"https:\/\/alcanzaclinical.com\/5704-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/alcanzaclinical.com\/"},{"@type":"ListItem","position":2,"name":"Alcanza Doses First Patient in Novel Alzheimer’s Trial"}]},{"@type":"WebSite","@id":"https:\/\/alcanzaclinical.com\/#website","url":"https:\/\/alcanzaclinical.com\/","name":"Alcanza Clinical Research","description":"Clinical Research for All","publisher":{"@id":"https:\/\/alcanzaclinical.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/alcanzaclinical.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Organization","@id":"https:\/\/alcanzaclinical.com\/#organization","name":"Alcanza Clinical Research","url":"https:\/\/alcanzaclinical.com\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/alcanzaclinical.com\/#\/schema\/logo\/image\/","url":"https:\/\/alcanzaclinical.com\/wp-content\/uploads\/2026\/11\/cropped-logo-300x59-1.webp","contentUrl":"https:\/\/alcanzaclinical.com\/wp-content\/uploads\/2026\/11\/cropped-logo-300x59-1.webp","width":300,"height":59,"caption":"Alcanza Clinical Research"},"image":{"@id":"https:\/\/alcanzaclinical.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=100082162274544","https:\/\/www.linkedin.com\/company\/alcanza-clinical"]},{"@type":"Person","@id":"https:\/\/alcanzaclinical.com\/#\/schema\/person\/7c0eb32da58e72e6d6f3bda3c4252349","name":"Sarah Belanus","url":"https:\/\/alcanzaclinical.com\/de\/author\/sarahcellsignalmarketing-com\/"}]}},"featured_image_src":"https:\/\/alcanzaclinical.com\/wp-content\/uploads\/2025\/08\/LinkedIn-Templates-9-600x400.png","featured_image_src_square":"https:\/\/alcanzaclinical.com\/wp-content\/uploads\/2025\/08\/LinkedIn-Templates-9-600x600.png","author_info":{"display_name":"Sarah Belanus","author_link":"https:\/\/alcanzaclinical.com\/de\/author\/sarahcellsignalmarketing-com\/"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/alcanzaclinical.com\/de\/wp-json\/wp\/v2\/posts\/5704","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alcanzaclinical.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alcanzaclinical.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alcanzaclinical.com\/de\/wp-json\/wp\/v2\/users\/22"}],"replies":[{"embeddable":true,"href":"https:\/\/alcanzaclinical.com\/de\/wp-json\/wp\/v2\/comments?post=5704"}],"version-history":[{"count":0,"href":"https:\/\/alcanzaclinical.com\/de\/wp-json\/wp\/v2\/posts\/5704\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alcanzaclinical.com\/de\/wp-json\/wp\/v2\/media\/5705"}],"wp:attachment":[{"href":"https:\/\/alcanzaclinical.com\/de\/wp-json\/wp\/v2\/media?parent=5704"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alcanzaclinical.com\/de\/wp-json\/wp\/v2\/categories?post=5704"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alcanzaclinical.com\/de\/wp-json\/wp\/v2\/tags?post=5704"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}